Shares of Auris Medical Holding AG (NASDAQ:EARS) shot up 14.1% during trading on Monday . The stock traded as high as $0.75 and last traded at $0.72. 1,546,487 shares changed hands during mid-day trading, an increase of 372% from the average session volume of 327,863 shares. The stock had previously closed at $0.64.

Several research firms recently commented on EARS. Roth Capital restated a “buy” rating and issued a $5.00 target price on shares of Auris Medical Holding AG in a research report on Saturday, July 1st. Zacks Investment Research upgraded Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Wednesday, August 30th. Finally, ValuEngine cut Auris Medical Holding AG from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $3.25.

The firm’s market cap is $30.77 million. The company’s 50 day moving average is $0.76 and its 200-day moving average is $0.76.

Auris Medical Holding AG (NASDAQ:EARS) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.09. On average, equities analysts anticipate that Auris Medical Holding AG will post ($0.63) earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in EARS. UBS Oconnor LLC acquired a new position in shares of Auris Medical Holding AG in the 1st quarter worth approximately $909,000. Perceptive Advisors LLC acquired a new position in shares of Auris Medical Holding AG in the 1st quarter worth approximately $368,000. Sabby Management LLC acquired a new position in shares of Auris Medical Holding AG in the 1st quarter worth approximately $133,000. Finally, Virtu KCG Holdings LLC acquired a new position in shares of Auris Medical Holding AG in the 2nd quarter worth approximately $101,000. 28.41% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Auris Medical Holding AG (EARS) Shares Up 14.1%” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/06/auris-medical-holding-ag-ears-shares-up-14-1.html.

Auris Medical Holding AG Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.